Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Background: High rate of cardiovascular disease (CVD) have been reported among patients with novel coronavirus disease (COVID-19). Meanwhile there were controversies among different studies about CVD burden in COVID-19 patients. Hence, we aimed to study CVD burden among COVID-19 patients, using a systematic review and meta-analysis.

Methods: We have systematically searched databases including PubMed, Embase, Cochrane Library, Scopus, Web of Science as well as medRxiv pre-print database. Hand searched was also conducted in journal websites and Google Scholar. Meta-analyses were carried out for Odds Ratio (OR) of mortality and Intensive Care Unit (ICU) admission for different CVDs. We have also performed a descriptive meta-analysis on different CVDs.

Results: Fifty-six studies entered into meta-analysis for ICU admission and mortality outcome and 198 papers for descriptive outcomes, including 159,698 COVID-19 patients. Results of meta-analysis indicated that acute cardiac injury, (OR: 13.29, 95% CI 7.35-24.03), hypertension (OR: 2.60, 95% CI 2.11-3.19), heart failure (OR: 6.72, 95% CI 3.34-13.52), arrhythmia (OR: 2.75, 95% CI 1.43-5.25), coronary artery disease (OR: 3.78, 95% CI 2.42-5.90), and cardiovascular disease (OR: 2.61, 95% CI 1.89-3.62) were significantly associated with mortality. Arrhythmia (OR: 7.03, 95% CI 2.79-17.69), acute cardiac injury (OR: 15.58, 95% CI 5.15-47.12), coronary heart disease (OR: 2.61, 95% CI 1.09-6.26), cardiovascular disease (OR: 3.11, 95% CI 1.59-6.09), and hypertension (OR: 1.95, 95% CI 1.41-2.68) were also significantly associated with ICU admission in COVID-19 patients.

Conclusion: Findings of this study revealed a high burden of CVDs among COVID-19 patients, which was significantly associated with mortality and ICU admission. Proper management of CVD patients with COVID-19 and monitoring COVID-19 patients for acute cardiac conditions is highly recommended to prevent mortality and critical situations.

© 2020 Elsevier Inc. All rights reserved.
2. Methods

2.1. Search strategy

In this study, Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guideline was used for study design, search strategy, screening and reporting. The research question has been developed using PECO; “P” stands for Patients, “E” as Exposure, “C” as Comparison and “O” as Outcome. PECO components were as follows: “P”; hospitalized COVID-19 patients, “E”; CVDs, “C”; no CVD, “O”; ICU admission/mortality. A systematic search was using all available MeSH terms and free keywords for “COVID-19”, “Cardiovascular Disease” “Myocardial Infarction”, “Heart Failure”, “Hypertension”, “Myocarditis”, “Arrhythmia”. Searched Databases included PubMed, Embase, Scopus, Web of Science, Cochrane Library, medRxiv pre-print database as well as Science Direct search engine. Hand search was done in publishers and journals databases including: Center for Disease Control and Prevention (CDC), The Journal of the American Medical Association (JAMA), The Lancet, The British Medical Journal (BMJ), Nature, Wiley, New England Journal of Medicine, Cambridge and Oxford. Our search included papers in all languages and there was no time limitation for publications. All original Cohort, Case Control, Cross-Sectional and Case-Series studies until 27th May 2020 were included.

2.2. Criteria for study selection

Two members of our team (F.P and A.H) selected the study independently and in case of disagreement R.A made the final decision. Studies met the following criteria included into systematic review: 1) Studies reporting characteristics of hospitalized COVID-19 patients; 2) Studies which reported any CVD in COVID-19 patients; 3) COVID-19 confirmed by Chest CT Scan, RT-PCR and hallmarks of the disease. Criteria for including studies into meta-analysis were: 1) Studies that reported CVD in COVID-19 patients admitted to ICU; 2) Studies reported the mortality rate of COVID-19 patients with underlying CVD; 3) Studies reported CVD among COVID-19 hospitalized patients. Studies were excluded if they: 1) Reported outpatients or asymptomatic COVID-19 patients; 2) Not reported CVDs; 3) Review papers, case reports, in vitro studies and animal studies.

The World Health Organization (WHO) reported cases of pneumonia with unknown source in Wuhan, China, December 2019 (8). Further investigations in samples of patients with respiratory infection, who were in contact with a seafood markets in Wuhan revealed a novel virus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (9). On 11th March, 2020 WHO declared the SARS-CoV-2 outbreak as a pandemic (10). It has been estimated that 1.7 billion people (22% world population) have at least one underlying condition, including cardiovascular diseases (CVD), which increases the risk of developing severe disease in case of coronavirus disease (COVID-19) (11).

There is a mutual relationships between CVD and infections (12,13), while the viral respiratory infectious diseases like influenza might increase the risk of myocardial infarction and cardiovascular events (13), underlying CVD might increase the risk of mortality among patients with infection (14).

Reports from COVID-19 disease including a large number of patients showed that fatality rate was 10.5% for CVD and 6.0% for hypertension among 72314 cases of COVID-19 (15). Studies indicated that there is an increased risk of mortality among hospitalized COVID-19 patients due to CVD (16-18).

Given the increasing number of COVID-19 patients besides from common clinical presentations of disease, CVD in COVID-19 infected patients are seems to be concerning (16). We aimed to assess the CVD burden of COVID-19, using a systematic review and meta-analysis method in this study.

2.3. Data extraction

Two investigators (F.P and A.H) have independently evaluated quality of publications and extracted data from included papers. In case of disagreement a supervisor (R.A) solved the issue and made the final decision. Data extraction included first author name, publication year, country and following data extracted for each group (Total Sample, ICU, Non-ICU, Mortality, Survival): Sample size, mean ± standard deviation (SD) of age, number of females, number of males, heart failure, hypertension, other cardiovascular disease, acute cardiac injury, cardiomyopathy, myocardial damage, heart palpitation, coronary heart disease, arrhythmia and acute cardiac injury. In cases that data was presented as median (interquartile range), a method by Wan et al. (19) was used to calculate mean ± SD.

2.4. Risk of bias assessment

Newcastle-Ottawa Scale tool was used for risk of bias assessment of studies included into meta-analysis (20). Risk of bias only assessed for studies entered into meta-analysis main outcomes (ICU and mortality) of the study (Fig. 1).

2.5. Data analysis

Odds Ratio (OR) and pooled estimate prevalence rate with 95% confidence interval (CI), were calculated using statistical analysis Comprehensive Meta-Analysis (CMA) V.2. In order to assess the heterogeneity, I-square (I²) test was used. In case of high heterogeneity (more than 50%) random effect model was used for meta-analysis. Publication bias has been assessed using Begg’s test.

3. Results

3.1. Study selection process

Our search through databases resulted in 4658 records. Duplicate records, including 1695 studies, have been excluded and after title and abstract screening, full texts of 2963 papers were assessed for eligibility. Four studies were excluded due to unavailability of the full-text. Finally, 56 papers (21-76) entered into meta-analysis for primary outcomes (mortality and ICU admission) and 198 papers [16,18,21–91,92–215] for descriptive outcomes. PRISMA flow diagram for the study selection process is presented in Fig. 2.

3.2. Study characteristics

Out of 56 papers included into meta-analysis for primary outcomes, 2 studies were case-control, 1 case-cohort, 8 case series and 45 cohorts. The studies’ sample size ranged from 13 to 11,095 including 29,056 participants. One-hundred ninety-nine papers entered into meta-analysis for primary outcomes (mortality and ICU admission) and 198 papers [16,18,21–91,92–215] for descriptive outcomes. PRISMA flow diagram for the study selection process is presented in Fig. 2.

3.3. Quality assessment

According to NOS tool for quality assessment, 56 studies earned the minimum eligibility score and entered into the meta-analysis for
primary outcomes. Summary of risk of bias is presented in Fig. 2. Begg’s test showed that there was no publication bias ($P = 0.7$).

3.4. Mortality

The meta-analysis showed that prevalence of CVDs among COVID-19 patients with mortality were as follows: Acute Cardiac Injury (52%), Hypertension (51%), Arrhythmia (37%), Heart Failure (27%), Coronary Heart Disease (23%) and Cardiovascular Diseases (23%) (Table 1).

Results of meta-analysis indicated that presence of Acute Cardiac Injury, Coronary Artery Disease, Arrhythmia, Hypertension, Heart Failure, and Cardiovascular Disease were significantly associated with mortality in COVID-19 patients (Table 2).

3.5. Intensive care unit admission

Meta-analysis of pooled prevalence of cardiovascular implications in COVID-19 patients admitted to ICU showed that hypertension (43%) was the most prevalent cardiovascular complication followed by arrhythmia (33%), acute cardiac injury (33%), coronary artery diseases (20%) and heart failure (20%) (Table 3).

The meta-analysis on ICU outcome showed that the odds of ICU admission in COVID-19 patients is significantly associated with Acute Cardiac Injury, Arrhythmia, Coronary Heart Disease, Cardiovascular Disease and Hypertension. Heart Failure was not significantly associated with ICU admission in COVID-19 however, the effect size was considerable (Table 4).

| Complication                 | Number of Studies | Heterogeneity | P-value | Pooled prevalence (95% CI) |
|------------------------------|-------------------|---------------|---------|---------------------------|
| Acute cardiac injury         | 13                | 64.33         | 0.00    | 0.52 (0.46, 0.59)         |
| Arrhythmia                   | 4                 | 89.08         | 0.00    | 0.37 (0.15, 0.67)         |
| Coronary heart disease       | 18                | 78.84         | 0.00    | 0.23 (0.18, 0.30)         |
| Heart failure                | 11                | 96.21         | 0.00    | 0.27 (0.17, 0.38)         |
| Hypertension                 | 38                | 81.38         | 0.00    | 0.51 (0.47, 0.55)         |
| Cardiovascular disease       | 18                | 91.84         | 0.00    | 0.23 (0.17, 0.30)         |

Table 1
Meta-analysis of pooled estimate prevalence of CVDs among COVID-19 patients with mortality.
A. Hessami, A. Shamshirian, K. Heydari et al. American Journal of Emergency Medicine 46 (2021) 382

3.6. Cardiovascular complications

One-hundred ninety-eight studies have investigated for cardiovascular complications in the COVID-19 patients. Pooled prevalence of cardiovascular complications observed among patients with COVID-19 included hypertension (29%), cardiovascular and cerebrovascular disease (14%), heart failure (10%), acute cardiac injury (16%), coronary heart disease (10%), myocardial damage (20%), cardiovascular disease (11%), arrhythmia (11%), cardiomyopathy (7%), heart palpitation (6%) and heart valve disease (9%) (Table 5, Fig. 3).

We have also analyzed pooled prevalence of cardiovascular disease in COVID-19 patient in different countries. Results of meta-analysis were as follows: Brazil (50.0%), China (7.8%), France (48.0%), Germany (45.5%), Iran (4.4%), Italy (24.7%), Netherlands (44.0%), South Korea (11.2%), Spain (16.9%), Switzerland (71.4%), United Kingdom (15.1%), and United States (24.4%) (Fig. 4).

4. Discussion

The results of this meta-analysis indicated cardiovascular implications including acute cardiac injury, arrhythmia, coronary heart disease, hypertension and cardiovascular diseases were significantly associated with COVID-19 patient’s admission to the ICU. Comparing pooled estimate of OR for CVDs showed odds of ICU admission was significantly higher in acute cardiac injury and arrhythmia than hypertension, but there was no significant difference between other cardiovascular implications. Investigations have shown that mortality in patients with acute cardiac injury was significantly higher than coronary artery disease, arrhythmia, and hypertension. Comparing estimated frequency of different cardiovascular complications including acute cardiac injury, arrhythmia, cardiomyopathy, coronary heart disease, heart palpitation, hypertension, myocardial damage, heart failure and other cardiovascular diseases did not show any significant difference among them.

Cardiovascular complications have been previously reported in previous respiratory infections with similar etiology and their condition affects severity of the disease (17,216); so that even hospitalization for pneumonia is associated with long-term and short-term risk of CVD (12). Viral infections cause imbalance between cardiac supply and demand and increase in systemic inflammation. Therefore patients with pre-existing CVD have higher risks for acute cardiac conditions (217), thrombosis (218), infection, and develop severe conditions during the infection (219).

Acute myocardial injury was significantly associated with both ICU admission and mortality. There were several etiologies proposed for acute myocardial injury in these patients. The first possible mechanism is myocardial injury caused by cytokine storm as the results of systemic inflammation mediated by pathologic T-cells (220-222). Study by Chen et al. (25) showed elevated myocardial injury biomarkers including NT-proBNP, cTnI and hs-CRP were significantly correlated with COVID-19 severity. The second possible explanation is the imbalance between supply and demand caused by systemic infection along with hypoxia caused by respiratory infection, which lead to acute myocardial injury (220,222). There are evidences that shows SARS-CoV-2 binds to human angiotensin converting enzyme-2 (ACE2) to infect the cells (223), which being highly expressed in lungs and heart. The binding of SARS-CoV-2 to ACE2 in heart can results acute myocardial injury (220,224). COVID-19 has been associated with thrombotic events and coagulations disorders (225), which might lead to hypercoagulability and coronary thrombosis results in acute myocardial infarction (220,222).

SARS-CoV-2 binding to ACE2 causes activation of renin-angiotensin system and its complications including hypertension, heart failure, and atherosclerosis (219,226,227) as we resulted in our meta-analysis. These data could also suggest a reason for high prevalence of hypertension in our pooled estimate. Underlying CVDs like hypertension could higher the risk of infection and developing more severe symptoms in COVID-19 patients [219]. We showed in our meta-analysis that hypertension was significantly associated with ICU admission and mortality; therefore blood pressure control could be potentially beneficial to reduce disease burden (228). Using Angiotensin Receptor Blockers (ARBs) and ACE inhibitors in order to control hypertension have raised question in the era of the COVID-19 pandemic. Studies suggested that using ARBs and ACE inhibitors could potentially be harmful as they can cause up-regulation of ACE2, SARS-CoV-2 receptor, and lung injury (228,229); so, they should be carefully considered in COVID-19 patients [219]. This meta-analysis also indicated that mean age of COVID-19 patients admitted to ICU was significantly higher than non-ICU. An

### Table 2

| Complication                  | Number of studies | Heterogeneity | Pooled OR (95% CI) | I-squared, % | P-value |
|-------------------------------|-------------------|---------------|--------------------|-------------|---------|
| Acute cardiac injury          | 12                |               | 13.29 (7.35, 24.03)| 0.00        | 0.00    |
| Heart failure                 | 8                 |               | 6.72 (3.34, 13.52) | 0.00        | 0.00    |
| Arrhythmia                    | 3                 | 0.00          | 2.75 (1.43, 5.25)  | 0.57        | 0.00    |
| Hypertension                  | 31                | 2.60          | 2.11, 3.19         | 0.00        | 0.00    |
| Cardiovascular disease        | 14                | 2.61          | 1.89, 3.62         | 0.00        | 0.00    |
| Coronary heart disease        | 16                | 3.78          | 2.42, 5.90         | 0.00        | 0.00    |

### Table 3

| Complication                  | Number of studies | Heterogeneity | Pooled prevalence (95% CI) | I-squared, % | P-value |
|-------------------------------|-------------------|---------------|----------------------------|-------------|---------|
| Acute cardiac injury          | 8                 | 0.33          | 0.24, 0.43                 | 0.04        | 0.00    |
| Arrhythmia                    | 3                 | 0.31          | 0.18, 0.51                 | 0.02        | 0.00    |
| Coronary heart disease        | 13                | 0.20          | 0.15, 0.27                 | 0.00        | 0.00    |
| Heart failure                 | 7                 | 0.20          | 0.09, 0.37                 | 0.00        | 0.00    |
| Hypertension                  | 31                | 0.43          | 0.37, 0.50                 | 0.00        | 0.00    |
| Cardiovascular disease        | 19                | 0.25          | 0.16, 0.35                 | 0.00        | 0.00    |

### Table 4

| Complication                  | Number of studies | Heterogeneity | Prevalence (95% CI) | I-squared, % | P-value |
|-------------------------------|-------------------|---------------|---------------------|-------------|---------|
| Coronary heart disease        | 60                | 0.10          | 0.09, 0.12          | 0.00        | 0.00    |
| Cardiovascular and cerebrovascular disease | 16 | 0.14          | 0.09, 0.22          | 0.00        | 0.00    |
| Cardiovascular disease        | 87                | 0.11          | 0.09, 0.12          | 0.00        | 0.00    |
| Arrhythmia                    | 17                | 0.11          | 0.07, 0.16          | 0.00        | 0.00    |
| Acute cardiac injury          | 28                | 0.16          | 0.13, 0.19          | 0.00        | 0.00    |
| Cardiomyopathy                | 8                 | 0.07          | 0.01, 0.27          | 0.00        | 0.00    |
| Heart failure                 | 3                 | 0.10          | 0.07, 0.13          | 0.00        | 0.00    |
| Myocardial damage             | 3                 | 0.20          | 0.06, 0.49          | 0.00        | 0.00    |
| Hypertension                  | 158               | 0.29          | 0.27, 0.31          | 0.00        | 0.00    |
| Heart palpitation             | 6                 | 0.06          | 0.03, 0.13          | 0.00        | 0.00    |
| Heart valve disease           | 3                 | 0.09          | 0.02, 0.16          | 0.00        | 0.00    |
explanation to this condition by AlGhatrif et al. (230) suggested that elderly patients with hypertension are more likely to have down-regulation of ACE2 expression, due to viral binding, and up-regulated angiotensin II, which exaggerates pro-inflammatory condition, predisposing them to severe conditions and mortality (231).

Arrhythmia was significantly associated with ICU admission and mortality in our meta-analysis. There are pathophysiological mechanisms suggested for arrhythmia among COVID-19 patients; however, whether these patients had pre-existing arrhythmia or secondary to COVID-19 remains unknown (232). First, as any systematic infection COVID-19 can cause electrolyte imbalance, especially hypokalemia (233), which might contribute to arrhythmia in susceptible patients (220). Second, as we have discussed earlier myocardial injury has been an important subject in COVID-19 patients. It has been suggested that myocardial damage can be potentially triggers arrhythmia (234,235). Third, pharmacological therapies prescribed for these patients can be potential risk factors for arrhythmia. Hydroxychloroquine, as one the most common drugs which had been used in COVID-19, can triggers QT prolongation (235,236). Fourth, arrhythmia could also occur secondary to myocarditis by disrupting cardiomyocyte membrane and electrolyte imbalance, myocardial fibrosis, proinflammatory cytokines and edema of pericardium (232).

In our meta-analysis the prevalence of heart palpitation was relatively high and it has been reported as one the initial symptoms of the disease [133]. National Health Commission of China (NHC) reported that some patients have presented with heart palpitations and chest tightness instead of cough and fever as initial symptoms of COVID-19 [219]; so, heart palpitations in outpatients setting needs to carefully considered as potential symptom of COVID-19.

Heart failure was significantly associated with mortality in our meta-analysis, ranked after acute cardiac injury. The incidence of heart failure might be as the consequence of myocardial injury or myocarditis (237), which has been previously discussed. Increasing systemic metabolic demand as the results of systemic infection could also exacerbate previous stable heart failure (220). Right heart failure and pulmonary hypertension should be also carefully considered in patients with acute respiratory distress syndrome (ARDS) and parenchymal lung disease (234). Cardiomyopathy has been also observed in COVID-19 patients in various forms. Takotsubo syndrome (TTS) or stress cardiomyopathy, characterized by transient left ventricular dysfunction, is triggered by emotional and physical stresses following to natural disasters (238), like COVID-19 pandemic. There were number of studies reported TTS in COVID-19 patients (239-243). Mechanism of stress cardiomyopathy in COVID-19 patients might be due to emotional distress caused by pandemic along with inflammatory and metabolic distress (241). Inflammatory cardiomyopathy or myocarditis was previously described in viral infections (244) as well as COVID-19 (245,246). Cardiomyocytes expresses ACE2 which is the receptor for SARS-CoV-2, so this virus could infects human heart which can even exacerbate in case of heart failure (232).

Coronary artery disease was significantly associated with mortality of COVID-19 patients in our study. In patients with previous coronary artery disease, inflammatory state and hemodynamic changes in infection can potentially increase the risk of plaque rupture (18,234,247).
Coagulopathy in COVID-19 patients (225) can also cause acute coronary syndrome in these patients.

We have discussed cardiovascular implications among COVID-19 patients. Cardiovascular diseases have significant role in the outcome of COVID-19 patients. Therefore, careful consideration and management of cardiovascular disease, from diagnosis to bedside, among COVID-19 patients are necessary. Results of this study could help policy makers, physicians and healthcare workers in front line to make evidence-based decisions and reduce the mortality and morbidity of this 21st century pandemic.

Limitation of this study was high heterogeneity of studies in population. Compounding effects of other co-morbidities in ICU admission and mortality was not being considered. It is possible that other co-morbidities related to respiratory system, renal system and gastrointestinal system affects patient’s condition. Cardiovascular implications could be pre-existing in patients or either developed by the infection; so, we could not determine the casual relationship. However, given the burden and vital role of CVDs the importance does not differ. We only included studies of hospitalized adult COVID-19 patients and asymptomatic and outpatients are excluded. Data regarding to cardiovascular diseases in COVID-19 patients in some countries were missing.

5. Conclusion

In conclusion, CVD have a significant role in disease severity and mortality of COVID-19 patients. Hypertension, acute cardiac injury, coronary heart diseases in COVID-19 patient needs to be carefully monitored and managed in case of acute conditions. Other cardiovascular implications, including arrhythmia and heart failure also need to be considered since they can be fatal. Therefore, careful consideration and management of cardiovascular disease among these patients are necessary. Results of this study could help policy makers, physicians and healthcare workers in front line to make evidence-based decisions and reduce the mortality and morbidity of this 21st century pandemic.

Ethics approval and consent to participate

This study has been approved by the Ethics Committee of Mazandaran University of Medical Sciences (IR.MAZUMS.REC.1399.087).

Consent for publication

Not applicable.

Funding

Student Research Committee, Mazandaran University of Medical Sciences (code number: 7396).

Declaration of Competing Interest

None of authors have declared any conflicts of interest.

Acknowledgements

We acknowledge Student Research Committee of Mazandaran University of Medical Sciences for supporting this project (code number: 7396).

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ajem.2020.10.022.

References

[1] Cheng VCC, Lau SKP, Woo PCY, Yuen KY. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev. 2007;20(4):690–94.
[2] Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–74.
[3] Saghaeizadeh A, Rezaei N. Immune-epidemiological parameters of the novel coronavirus - a perspective. Expert Rev Clin Immunol. 2020;16(5):465–70.
[4] Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24(6):490–502.
[5] Peiris J, Guan Y, Yuen K. Severe acute respiratory syndrome. Nat Med. 2004;10(12):588–97.
[6] Zaki AM, Van Boeheim S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814–20.
[7] Loffi M, Hambilin MR, Rezaei N. COVID-19: transmission, prevention, and potential therapeutic opportunities. Clin Chim Acta. 2020;508:254–66.
[8] World Health Organization. Pneumonia of Unknown Cause–China. Emergencies Preparedness, Response, Disease Outbreak News. World Health Organization (WHO); 2020.
[9] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–33.
[10] World Health Organization. WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19–11 March 2020 Geneva, Switzerland ; 2020.
[11] Clark A, Jit M, Warren-Gash C, Guthrie B, Wang HHX, Mercer SW, et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. Lancet Glob Health. 2020;8:e1003–17.
[12] Corses-Medina VF, Alvarez KN, Weissfeld LA, Slater CL, Tiao JR, Baldwin MR, Barr RG, et al. Characterization of clinical features of patients infected with the 2019 novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814–20.
[13] Dhainaut J-F, Claessens Y-E, Janes J, Nelson DR. Underlying disorders and their impact on COVID-19-11 March 2020 Geneva, Switzerland ; 2020.
[14] Madjid M, Miller CC, Zarubaev VV, Marinich IG, Kiselev OI, Lobzin YV, et al. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects. Eur Heart J. 2007;28(10):1205–10.
[15] Dhainaut J-F, Claessens Y-E, James J, Nelson DR. Underlying disorders and their impact on the host response to infection. Clin Infect Dis. 2005;41(Supplement_7):S88–9.
[16] Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239–42.
[17] Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5:811–8.
[18] Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of cardiovascular complications on the cardiovascular system: a review. JAMA Cardiol. 2020;5:831–40.
[19] S. Qin M, Shen B, Cai Y, Liu Y, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5:802–10.
[20] Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14(1):135.
[21] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.
[22] Argenziano MG, Bruce SL, Slater CL, Tiao JR, Baldwin MR, Barr RG, et al. Characterization and clinical course of 1000 Patients with COVID-19 in New York: retrospective case series. medRxiv. 2020. (2020.04.20.20072116).
[23] Bonetti G, Manelli F, Patrassi A, Bettinardi A, Borrelli G, Fiordalisi G, et al. Laboratory predictors of death from coronavirus disease 2019 (COVID-19) in the area of Valcamonica, Italy. Clin Chem Lab Med. 2020;58:100–1105.
[24] Caio J, Xu H, Cheng W, Yu L, Tu WJ, Liu Q. Clinical features and short-term outcomes of 18 patients with coronavirus disease 2019 in intensive care unit. Intensive Care Med. 2020;46(5):851–3.
[25] Cao M, Zhang D, Wang Y, Lu Y, Zhu X, Li Y, et al. Clinical features of patients infected with the 2019 novel coronavirus (COVID-19) in Shanghai, China. medRxiv. 2020.
[26] Chen J, Yan J, Zhou N, Zhao J, Wang D. Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48:E008.
[27] Chen C, Yi ZJ, Chang L, Shao HZ, Ming Z, Pei T, et al. The characteristics and death risk factors of 132 COVID-19 pneumonia patients with comorbidities: a retrospective single center analysis in Wuhan, China. medRxiv. 2020. (2020.05.07.20092882).
[28] Chen R, Liang W, Jiang M, Guan W, Zhan C, Wang T, et al. Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in China. Chest. 2020;158:97–105.
[29] Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368.
[30] Chen X, Zheng F, Qian Y, Ding S, Yang D, Lei C, et al. Epidemiological and clinical features of 291 cases with coronavirus disease 2019 in areas adjacent to Hubei, China: a double-center observational study. medRxiv. 2020.
identified through the U.S. coronavirus disease 2019 (COVID-19)-associated hospitalization surveillance network (COVID-NET). medRxiv. 2020.

[120] Kloek FA, Krupke MJBA, van der Meer NJM, Arbous MS, Gommers DAMP, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–7.

[121] Kolpin DA, Kulin S, Elisseeff O. Clinical and genetic characteristics of COVID-19 patients from UK Biobank medRxiv. 2020;2020.05.05.20075507.

[122] Kuno T, Takahashi M, Obata R, Maeda T. Cardiovascular comorbidities, cardiac injury and prognosis of COVID-19 in New York City. Am Heart J. 2020;226:24–5.

[123] Lala A, Johnson KW, Rusask AJ, Paranjie L, Zhao S, Solani S, et al. Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. medRxiv. 2020;2020.04.02.20072702.

[124] Latifi F, Farr MA, Clerkin KJ, Habal MV, Takeda K, Naka Y, et al. Characteristics and outcomes of reciprocating heart transplant with coronavirus disease 2019. JAMA Cardiol. 2020.e220159.

[125] Lac SF, Skik K, Zechnner P, Kessler HH, Kaufmann N, Koebelinger C, et al. Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series. Ann Intern Med. 2020;173:350–61.

[126] Li M, Dong Y, Wang H, Guo W, Zhou H, Zhang Z, et al. Cardiovascular disease potentially contributes to the progression and poor prognosis of COVID-19. Nutr Metab Cardiovasc Dis. 2020;30:1061–7.

[127] Li R, Tian J, Yang F, Li Y, Ju S, G, et al. Clinical characteristics of 225 patients with COVID-19 in a tertiary Hospital near Wuhan, China. J Clin Virol. 2020;127:104363.

[128] Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in COVID-19 in a tertiary Hospital in Wuhan, China. J Allergy Clin Immunol. 2020;145:994.e2–31.

[129] Liu J, Xin H, Xiao S, Cai H, Zhang S, Zheng L, et al. Analysis of epidemiological and clinical features in older patients with coronavirus disease 2019 (COVID-19) out of Wuhan. Clin Infect Dis. 2020;71:7480–7.

[130] Liu L, Liu J, Xin H, Hao S, Ji H, Li X, et al. Epidemiological, clinical, and virological characteristics of 465 hospitalized cases of coronavirus disease 2019 (COVID-19) from Zhejiang province in China. Infection Other Respi Viruses. 2020;14:564–74.

[131] Liu L, Li M, Wu J, Luo D, Zhu Y, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020;127.

[132] Liu L, Xu R, Zhang Y, Xuan W, Yan T, Pan K, et al. Patients of COVID-19 may benefit from sustained lopinavir-ritonavir combination and the increase of eosinophil may predict the outcome of COVID-19 progression. Int J Infect Dis. 2020;95:183–91.

[133] Liu L, Kang F-Y, Deng Y, Liu W, Wang M-F, Ma J-P, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl). 2020;133(9):104363.

[134] Liu R, Ming X, Zhu H, Song L, Gao C, Gao L, et al. Association of cardiovascular manifestations with in-hospital outcomes in patients with COVID-19: a hospital staff data. medRxiv. 2020.

[135] Liu Y, Xu J, Chen J, Yin P, Peng L, Wang HX, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect. 2020;81:e6-12.

[136] Lu L, Xiong W, Liu D, Liu Y, Yang D, Li N, et al. New-onset acute symptomatic seizure and death factors in coronavirus disease 2019: a retrospective multicenter study. Epilepsia. 2020;61:e49–53.

[137] Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurological manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77:883–90.

[138] Menter T, Hashbauer JD, Nienholf R, Savic S, Hopfer H, Deigendesch N, et al. Post-mortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variagated findings of lungs and other organs suggestive of vascular thrombosis. medRxiv. 2020.20072702.

[139] Miao C, Zhuang J, Jin M, Xiong H, Huang P, Zhao Q, et al. A comparative multi-centre study on the clinical and imaging features of confirmed and unconfirmed patients with COVID-19. medRxiv. 2020.

[140] Middeldorp S, Coppins M, van Haaps TF, Poppen M, Vlaar AP, Müller CA, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18:1995–2002.

[141] Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis. 2020.https://doi.org/10.1093/cid/ciaa270.

[142] Munk JL, van de Biggelaar R, Stohr J, Verweij J, Butting A, Wittens S, et al. The first 100 COVID-19 patients admitted to the Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands. Nederlands Tijdschr Geneeskd. 2020.164.

[143] Nie S, Zhao X, Zhao K, Zhang Z, Zhang Z. Metabolic disturbances and inflammatory dysfunction predict severity of coronavirus disease 2019 (COVID-19): a retrospective study. medRxiv. 2020.

[144] Niu S, Tian S, Lou J, Xie Z, Zhang L, Lian H, et al. Clinical characteristics of older patients infected with COVID-19: a descriptive study. Arch Gerontol Geriatr. 2020;89.

[145] Nunes Duarte-Neto A, de Almeida Monteiro RA, da Silva LFF, Malheiros D, de Oca Leandro R, Granato LR, et al. Cardiac inflammatory and arrhythmogenic effects of COVID-19 disease through ECG. Aging Male. 2020;1–9.

[146] Palaiodimos L, Kokkinidis DG, Li W, Karamanis D, Ognibene J, Arora S, et al. Severe obesity is associated with higher in-hospital mortality in a cohort of patients with COVID-19 in the Bronx, New York. Metabolism. 2020;108.
[148] Pavoni V, Gianellesio L, Pazzi M, Stere C, Meconi T, Frigeri FC. Evaluation of coagulation function by rotation thromboelastometry in critically ill patients with severe COVID-19 pneumonia. Thromb Haemost. 2020;120:281–6.

[149] Petrelli CM, Jones SA, Yang J, JagapathiBalan K, Lenchry N, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369: m2996.

[150] Piva S, Filippini M, Turla F, Cattaneo S, Margola A, De Furlus V, et al. Clinical presentation and initial management critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Brescia, Italy. J. Crit Care. 2020;56:25–32.

[151] Poyiadji N, Cormier P, Patel PY, Hadied MO, Bhargava P, Khanna N, et al. Acute pulmonary embolism and COVID-19. Radiology. 2020;201955.

[152] Qiu D, Yan X, Tang X, Peng J, Yu Q, Feng L, et al. Epidemiological and clinical features of 2019-nCoV acute respiratory disease cases in Hubei province, China: a retrospective, descriptive, multiple-center study. medRxiv. 2020.

[153] Qian G-C, Qian R-B, Ding F, Ma A-H, Wang Z-Y, Yin S-Y, et al. Epidemiologic and clinical characteristics of 91 hospitalized patients with COVID-19 in Zhejiang, China: a retrospective, multi-centre case series. QJM. 2020;113:474–81.

[154] Qian G-Q, Yang N-B, Ding F, Ma AHY, Wang Z-Y, Shen Y-F, et al. Epidemiologic and clinical characteristics of 2019 novel coronavirus (SARS-CoV-2) infection in Brescia, Italy. J Crit Care. 2020;51:390.

[155] Razavi AC, Kelly TN, He J, Fernandez C, Whelton PK, Krousel-Wood M, et al. Cardiovascular disease prevention and implications of COVID-19: an evolving case study in the Eastern Mediterranean region: the Khorshid COVID Cohort (KCC) study. medRxiv. 2020.11.06.20220777.

[156] Secco GG, Tarantini G, Mazzarotto P, Garbo R, Parisi R, Maggio S, et al. Invasive pulmonary embolism and COVID-19. Radiology. 2020:201955.

[157] Shi Y, Yu X, Zhao Z, Cui M, Chen D, Ai H, et al. Clinical characteristics and outcomes of 150 COVID-19-infected pneumonia critically ill patients: disease characteristics and surviving hospitalized patients with COVID-19 in Jiangsu province: a multicenter descriptive study. Clin Infect Dis. 2020:10.1093/cid/ciaa708.

[158] Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High value of chest CT of coronavirus disease 2019 (COVID-19) in the Xiaogan area. Radiology. 2020:201955.

[159] Vahidy FS, Nicolas JC, Meeks JR, Khan O, Jones SL, Masud F, et al. Racial and ethnic differences in disparities of SARS-CoV-2 pandemic: analysis of a COVID-19 observational registry for a diverse U.S. metropolitan population. medRxiv. 2020.04.24.20073148.

[160] Vicenì Z, Di Cosola R, Rustica M, Ratti A, Rota I, Fera P, et al. The liaison between respiratory failure and high blood pressure: evidence from COVID-19 patients. Eur Respir J. 2020;56:1250–7.

[161] Vicenzi E, Chebbou M, Poissy J, Raverdy V, Noullet J, Chetboun M, et al. The liaison between respiratory failure and high blood pressure: evidence from COVID-19 patients. Eur Respir J. 2020;56:1250–7.

[162] Wan S, Yang F, Feng Z, Zheng Y, Li B, Hu Y, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol. 2020;92:797–806.

[163] Wang K, Kang S, Tian J, Zhang X, Wang Y. Imaging manifestations and diagnostic value of chest CT of coronavirus disease 2019 (COVID-19) in the Xiangya hospital. Clin Radiol. 2020;75(5):341–7.

[164] Wang W, He J. Wu S. The definition and risks of cytokine release syndrome-like in 11 COVID-19-infected pneumonia critically ill patients: disease characteristics and retrospective analysis. medRxiv. 2020.

[165] Wang X, Feng J, Zhu Y, Chen L, Ding F, Zhou R, et al. Clinical characteristics of critically ill patients with novel coronavirus infection (COVID-19) in a Fangcang Hospital. Clin Infect Dis. 2020;60:1012–4.

[166] Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis. 2020:71:769–77.

[167] Wei JF, Huang FY, Xiong TY, Liu Q, Chen H, Wang H, et al. Acute myocardial injury is common in patients with covid-19 and improves their prognosis. Heart. 2020;106:1122–3.

[168] Wright FL, Vogler TO, Moore EE, Moore HB, Wohlauer MW, Urban S, et al. Fibrinolysis shutdown correlates to thromboembolic events in severe COVID-19 infection. J Am Coll Surg. 2020;321:193-203.e1.
[206] Zhao XY, Xu XX, Yin HS, Hu QM, Xiong T, Tang YY, et al. Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study. BMC Infect Dis. 2020;20(1).

[207] Zhao Z, Xie J, Yin M, Yang Y, He H, Jin T, et al. Clinical and laboratory profiles of 75 hospitalized patients with novel coronavirus disease 2019 in Hefei, China. medRxiv. 2020.

[208] Zheng F, Tang W, Li H, Huang YK, Xie YL, Zhou ZG. Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha. Eur Rev Med Pharmacol Sci. 2020;24(6):3404–10.

[209] Zhang Y, Sun LJ, Xu M, Pan J, Zhang YT, Fang XL, et al. Clinical characteristics of 34 COVID-19 patients admitted to intensive care unit in Hangzhou, China. J Zhejiang Univ Sci B. 2020;21(5):378–87.

[210] Zhou B, She J, Wang Y, Ma X. The clinical characteristics of myocardial injury in severe and very severe patients with 2019 novel coronavirus disease. J Infect. 2020; 81:147–78.

[211] Zhou F, Yu X, Tong, X, Zhang R. Clinical features and outcomes of 197 adult discharged patients with COVID-19 in Yichang, Hubei, medRxiv. 2020.

[212] Zhou Y, He Y, Yang H, Yu H, Wang T, Chen Z, et al. Development and validation a nomogram for predicting the risk of severe COVID-19: a multi-center study in Shuhan, China. PLoS One. 2020;15(5):e0233238.

[213] Zhou Z, Zhao N, Shu Y, Han S, Chen B, Shu X. Effect of gastrointestinal symptoms in patients with COVID-19. Gastroenterology. 2020;158(8):2294–301.

[214] Zhou B, She J, Wang Y, Ma X. The clinical characteristics of myocardial injury in severe and very severe patients with 2019 novel coronavirus disease. J Infect. 2020; 81:147–78.

[215] Zhu Z, Tang J, Chai X, Fang Z, Liu Q, Hu X, et al. How to differentiate COVID-19 pneumonia from heart failure with computed tomography at initial medical contact during epidemic period. medRxiv. 2020.

[216] Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis. 2020;95:332–9.

[217] Zhu H, Rhee J-W, Cheng P, Waliany S, Chang A, Witteles RM, et al. Cardiovascular complications in patients with COVID-19: consequences of viral toxicities and host immune response. Curr Cardiol Rep. 2020;22(5):32.

[218] Connors JM, Levy JL. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033–40.

[219] Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular system. Nat Med. 2020;26(1):55.

[220] Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr. 2020;14(S1):60.

[221] Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. Coronavirus disease 2019 (COVID-19) and cardiovascular disease. Circulation. 2020;141:1648–55.

[222] South AM, Diez D, Chappell MC. COVID-19, ACE2 and the cardiovascular consequences. Am J Physiol Heart Circ Physiol. 2020;318:H1084–90.

[223] Schiffmann EL, Hack JM, Isi, Munter P, Webb RC. Hypertension and COVID-19. Am J Hypertens. 2020;33(5):373–4.

[224] Fang L, Karakikulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21.

[225] Al-Ghatrif M, Cingolani O, Lakatza EG. The dilemma of coronavirus disease 2019, aging, and cardiovascular disease: insights from cardiovascular aging science. JAMA Cardiol. 2020;5:747–8.

[226] Yazdanpanah F, Hamblin MR, Rezaei N. The immune system and COVID-19: friend or foe? Life Sci. 2020;256:117900.

[227] Siripanthong B, Nazerian S, Muser D, Deo R, Santangelo P, Khanyi MJ, et al. Recognizing COVID-19-related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm. 2020;17:1463–71 (S1547-5271(20)30422-7).

[228] Lazzarini PE, Boutjdiri M, Capecchi PL. COVID-19, arrhythmic risk and inflammation: mind the gap! Circulation. 2020;142:7–9.

[229] Wu C-I, Postema PC, Arbelo E, Behr ER, Bezzina CR, Napolitano C, et al. SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes. Heart Rhythm. 2020;17:1456–62 (S1547-5271(20)30285-X).

[230] Tomasoni D, Italia L, Adamo M, Inciardi RM, Lombardi CM, Solomon SD, et al. COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. Eur J Heart Fail. 2020;22:957–66.

[231] Medina de Chazal H, Del Bueno MG, Keyser-Marcus L, Ma L, Moeller FG, Berrocal D, et al. Stress cardiomyopathy diagnosis and treatment. JACC State-of-the-Art Review. J Am Coll Cardiol. 2018;72(16):1955–71.

[232] Fung G, Luo H, Qiu Y, Yang D, McManus B, Yang T, et al. Takotsubo cardiomyopathy in males with Covid-19. J Am Coll Cardiol. 2020;75(18):2352–71.

[233] Driggin E, Madhavan MV, Bikdeli B, Chughtai A, Jafri S, Benokraitis N, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. 2020;75(18):2352–71.

[234] Al-Ghatrif M, Cingolani O, Lakatza EG. The dilemma of coronavirus disease 2019, aging, and cardiovascular disease: insights from cardiovascular aging science. JAMA Cardiol. 2020;5:747–8.

[235] Yao G, Wang X, Wang L, Li Y, Jiang Y, Wei N, et al. COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. Eur J Heart Fail. 2020;22:957–66.

[236] Giustino G, Croft LB, Oates CP, Rahman K, Lerakis S, Reddy VY, et al. Takotsubo cardiomyopathy with COVID 19. Eur Heart J Cardiovasc Imaging. 2020;21:1052 jeaa152.

[237] Giustino G, Croft LB, Oates CP, Rahman K, Lerakis S, Reddy VY, et al. Takotsubo cardiomyopathy with COVID-19. Eur Heart J Cardiovasc Imaging. 2020;21:1052 jeaa152.

[238] Tomasoni D, Italia L, Adamo M, Inciardi RM, Lombardi CM, Solomon SD, et al. COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. Eur J Heart Fail. 2020;22:957–66.

[239] Medina de Chazal H, Del Bueno MG, Keyser-Marcus L, Ma L, Moeller FG, Berrocal D, et al. Stress cardiomyopathy diagnosis and treatment. JACC State-of-the-Art Review. J Am Coll Cardiol. 2018;72(16):1955–71.

[240] Pasqualotto MC, Secco E, Nizzetto M, Scevola M, Alfarati L, Cester A, et al. Stress cardiomyopathy in COVID-19 disease. Eur J Case Rep Intern Med. 2020;7(6):001718.

[241] Chatterjee A, Bhatia H, Biswas S, Bhatia S, Singh P, Nigam P, et al. COVID-19 pandemic: a new direction for treatment of cardiovascular diseases. J Med Virol. 2020;92(7):902–8.

[242] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):497–506.

[243] Chatterjee A, Bhatia H, Biswas S, Bhatia S, Singh P, Nigam P, et al. COVID-19 pandemic: a new direction for treatment of cardiovascular diseases. J Med Virol. 2020;92(7):902–8.

[244] Fung G, Luo H, Qiu Y, Yang D, McManus B, Yang T, et al. Takotsubo cardiomyopathy in males with Covid-19. J Am Coll Cardiol. 2020;75(18):2352–71.

[245] Giustino G, Croft LB, Oates CP, Rahman K, Lerakis S, Reddy VY, et al. Takotsubo cardiomyopathy with COVID 19. Eur Heart J Cardiovasc Imaging. 2020;21:1052 jeaa152.

[246] Giustino G, Croft LB, Oates CP, Rahman K, Lerakis S, Reddy VY, et al. Takotsubo cardiomyopathy with COVID-19. Eur Heart J Cardiovasc Imaging. 2020;21:1052 jeaa152.